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Abstract
Symptomatic intestinal strictures develop in more 
than one third of patients with Crohn’s disease (CD) 
within 10 years of disease onset. Strictures can 
be inflammatory, fibrotic or mixed and result in a 
significant decline in quality of life, frequently requiring 
surgery for palliation of symptoms. Patients under 
the age of 40 with perianal disease are more likely to 
suffer from disabling ileocolonic disease thus may have 
a greater risk for fibrostenotic strictures. Treatment 
options for fibrostenotic strictures are limited to 
endoscopic and surgical therapy. Endoscopic balloon 
dilatation (EBD) appears to be a safe, less invasive 
and effective alternative modality to replace or defer 
surgery. Serious complications are rare and occur in 
less than 3% of procedures. For non-complex strictures 
without adjacent fistulizaation or perforation that are 
less than 5 cm in length, EBD should be considered as 
first-line therapy. The aim of this review is to present 
the current literature on the endoscopic management of 
small bowel and colonic strictures in CD, which includes 
balloon dilatation, adjuvant techniques of intralesional 
injection of steroids and anti-tumor necrosis factor, and 
metal stent insertion. Short and long-term outcomes, 
complications and safety of EBD will be discussed. 
Key words: Endoscopy; Crohn’s disease; Stricture; 
Stenosis; Inflammatory bowel disease; Endoscopic 
balloon dilation
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Core tip: Endoscopic balloon dilation (EBD) for Crohn’s 
disease-related fibrostenotic strictures has been rec-
ognized as a safe, and less invasive intervention with rare 
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complications that occur in less than 3% of procedures. 
EBD can replace or defer surgery and help avoid 
frequent intestinal resections, which result in short bowel 
syndrome and impair quality of life. For non-complex 
strictures without adjacent fistulization or perforation that 
are less than 5 cm in length, EBD should be considered 
as first-line therapy. In this review we discuss safety, 
short and long-term outcomes, as well as adjuvant 
techniques of intralesional injection of steroids, anti-
tumor necrosis factor, and metal stent insertion. 
Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche 
G. Endoscopic management of Crohn’s strictures. World J 
Gastroenterol 2018; 24(17): 1859-1867  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v24/i17/1859.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v24.i17.1859
IntroductIon
Intestinal strictures are a common complication of 
Crohn’s disease (CD) affecting one-third of the patient 
population within 10 years of disease onset. This number, 
however, is likely under-reported[1,2]. In general, CD 
strictures are classified into inflammatory, fibrotic or 
mixed, although all symptomatic inflammatory strictures 
likely have some component of fibrosis and vice-versa[2,3]. 
Risk factors and predictors of intestinal strictures to 
date are clinical, environmental, genetic or endoscopic 
parameters[4] (Table 1). Although no clinical factors exist 
which can accurately predict the stricturing phenotype 
of CD, there do exist factors which may predict the 
likelihood of small bowel disease and a disabling disease 
course thus indirectly may suggest an increased risk for 
the development of fibrostenotic disease. These factors 
include the presence of perianal disease, age of CD 
diagnosis less than 40 years old and the need for steroids 
during the first flare[4,5]. Patients frequently complain 
of progressive post-prandial abdominal pain, bloating, 
nausea, vomiting and weight loss. The diagnosis of 
intestinal strictures usually coincides with a spiraling 
decline in quality of life and results in surgery in 75% of 
patients at least once during their lifetime[1]. CD patients 
will frequently undergo multiple bowel resections over 
their lifetime that repeatedly exposes them to immediate 
and long-term post-operative complications such as 
anastomotic leaks with intra-abdominal sepsis, short 
bowel syndrome, and adhesions with recurrent bowel 
obstructions[2,6]. 
The pathogenesis of CD complications develops from 
chronic accumulation of inflammatory bowel damage 
variably leading to stricture, fistula and/or abscess 
formation[2]. Stricture development, although not fully 
understood, involves the progressive deposition of 
extracellular matrix protein (ECM) produced by myofi-
broblasts at variable sites of the bowel being injured 
by chronically uncontrolled relapsing and remitting 
transmural inflammation[7]. During chronic intestinal 
inflammation, the baseline release of profibrotic 
cytokines (e.g., IL-4 and IL-13) increases over time 
further accelerating the process of excessive matrix 
deposition[7,8]. There may also exist a point where 
inflammation is no longer required to trigger fibrosis. 
As ECM is deposited during chronic inflammation, the 
bowel wall becomes stiffer. Bowel wall stiffness acts 
independently as a mesenchymal cell activator, resulting 
in ongoing myofibroblast stimulation, thus progressive 
fibrotic stenosis[9]. 
Treatment options for fibrostenotic strictures are 
limited to endoscopic and surgical therapy (i.e., strictur-
oplasty and small bowel resection)[10]. Fortunately, most 
de novo strictures form in the ileum and ileocolic regions, 
which are accessible by ileocolonoscopy or balloon-
assisted enteroscopy[11]. Although pharmacotherapy 
may delay the time before operative management, it 
has not been shown to prevent it[12]. Approximately 
80% of patients will have their first bowel resection 
10 years following their diagnosis of CD[2]. To date no 
specific intestinal anti-fibrotic therapy exists, nor has any 
immunosuppressant or biologic therapy been shown to 
prevent stricture formation.
The following review presents the current data 
on the endoscopic management of small bowel and 
colonic strictures in CD. Short and long-term outcomes, 
complications and a description of the procedure will be 
discussed. 
EFFIcAcY oF EndoScoPIc BALLoon 
dILAtIon
Endoscopic balloon dilation (EBD) is a minimally 
invasive bowel-length preserving mean of managing 
symptomatic CD patients with short fibrotic strictures 
(Figure 1). EBD has become an established modality of 
therapy and often plays an important role in delaying or 
acting as a bridge to surgery[10,13]. The most common 
location of the small bowel to undergo EBD using a 
colonoscope is the distal ileum or at the ileocolonic 
anastomosis of a patient following a small bowel 
resection[14]. Strictures located in the distal duodenum 
to proximal jejunum or distal jejunum to proximal ileum 
may be accessed with ante- or retrograde enteroscopy, 
respectively[15].  
Short- and long-term efficacy has been inconsistently 
defined in studies[13]. In general, short-term efficacy has 
been described as the technical success of the procedure 
or the ability to traverse the dilated area freely with the 
endoscope immediately after dilatation[13,16]. Long-term 
efficacy, in most studies, has been described as the time 
elapsed until another intervention (either surgical or 
endoscopic) is required[2,13,16]. Despite the lack of a formal 
definition, excellent short- and moderate long-term 
efficacy of EBD for CD strictures has been documented 
in many studies[14,16,17]. Table 2 shows a summary of 
published studies on EBD using conventional colonoscopy 
in CD patients. In a systematic review and descriptive 
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pooled analysis of 12 studies conducted between 1991 
to 2013 evaluating 1463 CD patients who underwent 
3213 EBD procedures, the technical success rate was 
89% with an associated relief of clinical symptoms in 
81% of patients[14]. The majority of strictures were ileal 
(98.6%) at anastomotic sites (62%), which were 2 
cm or less. However, the recurrence rate of strictures 
was high. At the 36.6 mo median follow-up, 47.5% of 
patients had symptomatic recurrence and 28.6% of all 
patients had required surgical intervention. This study 
concluded that the chance of requiring repeat EBD or 
surgical intervention at 2 years was 73.5% and 42.9%, 
respectively[14]. Another large recent systematic review 
with meta-analysis involving 1089 patients (2664 EBDs) 
across 25 studies revealed similar results[17]. The technical 
success rate was 92.3% with a reported symptomatic 
response rate of 70.4%. The proportion of patients 
requiring a repeat dilation after 1 and 2 years was 
31.6% (160/506) and 25.9% (117/451), respectively. 
Most patients within 5 years required recurrent dilations 
(80%) and/or surgical interventions (75%)[17]. Of 
interest is the lower symptomatic success rate as 
compared to the technical success rate across studies. 
This likely occurred due to a lack of a standardized 
means of reporting technical and clinical efficacy and/or 
a superimposed process existing that contributed to 
the patient’s symptoms (e.g., ongoing inflammation, 
intestinal bacterial overgrowth, IBS, etc.)[10]. Despite this 
discrepancy, the short-term clinical success rate remains 
high. 
In the setting of small bowel strictures not in reach 
of the enteroscope or colonoscope, the double balloon 
enteroscope can be used in an antegrade or retrograde 
fashion for diagnostic and/or therapeutic intervention[15]. 
Although there are only a few small studies which have 
evaluated its use in dilating small bowel CD strictures, 
the results were positive[18,19]. Nishida et al[20] performed 
a retrospective review on their center’s experience 
with dilating small bowel strictures between 2006 to 
2015. Overall, small bowel dilation using the double 
balloon enteroscope was found to be successful but 
there was a greater risk for requiring surgery in patients 
with multiple strictures as compared to those with a 
single stricture (adjusted hazard ratio, 14.94; 95%CI: 
1.91-117.12; p = 0.010)[20]. As such, a single stricture 
but not necessarily multiple strictures may be a good 
indication for considering dilation using the double 
balloon enteroscope. 
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Table 1  Risk factors and predictors of fibrostenosing Crohn’s disease
Clinical[4] Age at diagnosis < 40 yr
Perianal disease at diagnosis 
Need for steroids during first flare
Small bowel disease location
Prior appendectomy
Environmental[4] Smoking
Endoscopic[4] Deep mucosal ulcerations
Genetic[4] Nucleotide oligomerisation domain 2 (NOD2) variants
Janus-associated kinase 2 (JAK2)
Caspase-recruitment domain 15 (CARD15) 
NOD2/CARD15 mutations on both chromosomes
TNF superfamily 15 (TNFSF15) in Asians
5T5T in the MMP3 gene
rs1363670
Serological[4] Antimicrobial antibodies
anti-Saccharomyces cerevisiae antibodies (ASCA) IgA in Asians
Figure 1  Endoscopic balloon dilatation of ileocolonic anastomosis (A) and endoscopic appearance post endoscopic dilatation (B).  
A B
Bessissow T et al . Endoscopic management of CD
1862 May 7, 2018|Volume 24|Issue 17|WJG|www.wjgnet.com
for post-surgical strictures as compared to native 
strictures (OR = 2.3, p < 0.001). Similarly, a recent 
study published by the Cleveland Clinic group after 
performing a retrospective review on 307 patients who 
had undergone either EBD or surgical resection for an 
ileocolonic anastomotic stricture had worse short-term 
outcomes (i.e., technical success) but similar long-term 
outcomes as compared to the aforementioned studies 
evaluating EBD of de novo strictures[24]. Of the 176 
patients who had undergone EBD, the technical success 
rate was 86% (range 71% to 100%) with a long-term 
clinical efficacy, defined as an avoidance of surgery, of 
58% over a follow-up period of 33 mo[24]. The presence 
of active inflammation identified on endoscopy, elevated 
CRP, medical treatment after dilation, cigarette smoking 
and intralesional steroid injection have demonstrated 
conflicting results with respect to the need for surgery 
and successful EBD[2,17,23,24]. 
EndoScoPIc AdJuVAnt tEcHnIQuES 
Intralesional injection of steroids has been demon-
PrEdIctorS oF SuccESSFuL 
EndoScoPIc dILAtAtIon
Factors that are predictive of a successful EBD include 
short straight strictures in-line with the bowel lumen 
distal to the duodenum, which are non-ulcerated in 
a location without any adjacent abscess and at least 
5 cm from a fistula orifice[21,22]. Strictures located in 
the duodenum were found to have a 5 fold increased 
hazard for time to shorter surgery as compared to 
strictures located in the jejunum/ileum or colon (HR = 
4.7, p = 0.038; HR = 5.6, p = 0.03; respectively)[23]. 
Additionally, a stricture length ≤ 5 cm was associated 
with a lower chance of requiring surgical intervention 
following EBD (HR = 2.5, 95%CI: 1.4-4.4; p = 
0.002). For every 1 cm increase in stricture length, 
the risk for surgery increased by 8% (p = 0.005)[23]. 
In contrast to popular belief, anastomotic strictures 
have been associated with poorer short-term outcomes 
than de novo strictures[23,24]. This was highlighted in 
the aforementioned review by Bettenworth et al[14] 
which documented a lower technical success rate 
Table 2  Summary of published studies on endoscopic balloon for Crohn’s disease strictures









Blomberg et al[52] 1991   27 100 25 100   67   0
Williams et al[53] 1991     7   71 20   71   71   0
Breysem et al[54] 1992   18   78 18   89   50   0
Cockuyt et al[55] 1995   55   67 20   85   62   8
Ramboer et al[56] 1995   13   69 18 100 100   0
Matsui et al[57] 2000   55   43 20   86   78   2
Dear et al[58] 2001   22   95 18 100   73   0
Brooker et al[59] 2003   14   79 20 100   79   0
Morini et al[60] 2003   43   67 18   79   42   0
Sabate et al[61] 2003   38   68 25   84   53   3
Thomas-Gibson et al[62] 2003   59   90 18   73   41   3
Singh et al[63] 2005   17   35 20 100   76 18
Aljouni et al[64] 2006   37   37 20   90   87   3
Ferlitsch et al[65] 2006   46   59 20   85   66   4
Nomura et al[66] 2006   16   35 20   94   65   6
Foster et al[67] 2008   24   41 20   92 NA 13
Hoffman et al[68] 2008   25   57 20 100   52 16
Stienecker et al[69] 2009   25   42 18   97   94   3
Mueller et al[70] 2010   55   23 18   95   76   2
Thienpont et al[71] 2010` 138   84 18   97   76   3
Scimeca et al[72] 2011   37   90 20   84   89   0
Gustavsson et al[51] 2012 178   80 25   89   64 11
Karstensen et al[73] 2012   23   24 15   83   74      1.9
De’Angelis et al[74] 2013   26   52 18 100   93   2
Endo et al[75] 2013   30   36 20   94   64 10
Honzawa et al[76] 2013   25   21 20   88   62 12
Nanda et al[77] 2013   31 100 18 100   45   0
Atreja et al[78] 2014 128   48 20   83   67   3
Bhalme et al[79] 2014   79   61 20   95   77   0
Hagel et al[80] 2014   77   57 20   55   65 10
Krauss et al[81] 2014   20   25 18 100 NA 14
Ding et al[82] 2016   54 100 20   89   82   2
Clinical efficacy was defined according to each study (i.e., resolution of obstructive symptoms after dilation with the avoidance of surgery or additional 
intervention). Technical success was defined by successful passage of the endoscope or colonoscope immediately after dilation. Clinical efficacy was defined 
as the resolution of obstructive symptoms after dilation with the avoidance of surgery. Major complications (calculated per number of dilations) included 
were perforations, bleeding, intra-abdominal abscesses or fistulas. NA: Not available.
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strated to be effective for peptic, corrosive, anastomotic 
or post-radiotherapy fibrotic strictures[25]. However, 
strong evidence for the use of intralesional injection 
of steroids in CD is lacking[25-28]. Studies that have 
evaluated its use in CD have used the formulation 
triamcinolone due to its rapid onset of action and long-
lasting duration of effectiveness of 3-4 wk[29]. Only two 
small randomized placebo controlled studies have been 
performed evaluating the use of intralesional steroids 
versus saline injection after failing medical therapy 
and EBD. The first study conducted in 2007, included 
13 adult patients with short (≤ 5 cm) ileocolonic 
anastomotic strictures[30]. Five of the seven patients 
in the intervention group required re-dilation after the 
procedure and one patient had a complication versus 
one of six in the placebo group required re-dilation. 
There was no significant difference with respect to 
success of the procedure between groups[30]. This 
trial was stopped early due to the trend toward harm 
and remains the influential study behind the current 
American College of Gastroenterology and British 
Society of Gastroenterology position statements against 
the routine use of intralesional steroids[31,32]. The second 
study published in 2010 included 29 pediatric patients 
with short ileal or colonic strictures (12 anastomotic, 
17 de novo)[33]. In contrast, this study did demonstrate 
a reduction in time to re-dilation and surgery in the 
intervention group. Within the sub-group of patients 
evaluated in a recent large systematic review evaluating 
the management of CD strictures, intralesional steroid 
injection did not improve outcomes[33]. Similarly, a 
review conducted in 2013 summarizing the findings 
from five retrospective case-series evaluating the use of 
intralesional steroids in CD patients concluded the data 
to be contradictory and limited[34]. 
Although controversial, intralesional injection of 
anti-tumor necrosis factor has been evaluated in 
patients with small bowel and colonic CD strictures with 
promising results, but concerns related to immunization 
may limit its potential as a therapeutic option[35,36]. One 
small case series evaluated the effect of a 90-120 mg 
intralesional injection of infliximab in three symptomatic 
patients with colonic CD strictures. All three patients had 
an improved endoscopic appearance of the stricture as 
well as relief of their obstructive symptoms for at least 
four months following the injection[35]. Similarly, another 
small case series evaluating intralesional injections 
of 40 mg of infliximab into small bowel CD strictures 
combined with EBD in six patients was associated with 
improved symptoms and a reduction in their modified 
simple endoscopic score for Crohn’s disease (SES-
CD)[37]. The results of a larger randomized controlled 
trial evaluating the efficacy of performing intralesional 
injections of adalimumab into intestinal CD strictures 
are awaited[38]. 
Endoscopic metal stent insertion has been attemp-
ted in few patients with CD strictures. Although the 
technical success rate has been reportedly high, major 
complications such as bowel perforation, stent migration 
and fistulization was reported in 67% of patients[39]. 
Additionally, in order to avoid stent impaction, most 
studies suggest removing the stent after one month[40-42]. 
One small prospective cohort study concluded the risk 
for complications was too high to suggest the use of 
endoscopic metal stents as a treatment option for CD 
strictures after evaluating the data from 11 patients at 
their center[40]. The use of biodegradable instead of metal 
stents has been evaluated recently in a case-series last 
year involving six patients with intestinal and colonic 
CD strictures. Although technical success was good, 
Table 3  Practical considerations
Predictors favoring successful dilation[11,22-25] Symptomatic predominantly fibrotic stricture 
Short (≤ 5 cm) stricture
Single straight stricture 
Stricture distal to the duodenum
Anastomotic stricture more favorable than de novo stricture
First dilation
Lack of a superimposed process contributing to symptoms (e.g., SIBO or IBS)
Risk factors for complications[22-25] Predominantly inflammatory stricture without medical optimization
Stricture greater than 5 cm 
Multiple small bowel strictures
Strictures caused by extrinsic compression (e.g., adhesions)
Fistulization within 5 cm of the area to be dilated
Adjacent perforation or intra-abdominal collection
Complete small bowel obstruction
Tortuous or tethered small bowel or significant stricture angulation
Duodenal stricture
1Short term outcome[15,18] 85%-95% (technical success), 70%-80% (clinical response)
2Long term outcome[15,18] 32% (year 1 post dilation), 80% (year 5 post dilation)
3Complication rate[25,45] 1%-4%
1Short term outcome refers to the time elapsed immediately after the dilation takes place; technical success refers to the ability to successfully complete 
the dilation; clinical response refers to the symptomatic improvement of the patient immediately following the dilation; 2Long term outcome refers to the 
percentage of patients requiring a repeat intervention; 3Complication rate encompasses only major complications requiring urgent intervention such as 
bleeding, perforation and infection.
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premature stent failure occurred in all of the patients[43].  
SAFEtY oF EndoScoPIc BALLoon 
dILAtIon
Although EBD is a minimally invasive procedure, bowel 
perforation and severe bleeding has been reported in 
most large studies[17,23,24]. In the aforementioned review 
by Bettenworth et al[14], major complications requiring 
hospitalization occurred in 2.8% of patients. Similarly, 
another large systematic review evaluating 24 non-
randomized studies including 1163 patients found the 
rate of iatrogenic perforation to be 3%[44]. The rate for 
major complications including infection and hemorrhage 
in this study was 4%[44]. In a study directly comparing 
EBD to surgical intervention for the management of 
intestinal CD strictures, perforation occurred in 1.1% 
of the patients in the EBD group whereas the post-
operative complication rate (e.g., intra-abdominal sepsis) 
was 8.8%[24]. Despite these significant complications, 
no deaths have been reported to date. Since benign or 
inflammatory intestinal strictures are indistinguishable 
from early adenocarcinoma on imaging, there exists 
a risk that malignancy may be missed when EBD is 
performed instead of surgical excision[3]. Population based 
studies have suggested a greater risk for small bowel 
malignancy in patients with longstanding CD. Several 
case reports exist documenting the development of small 
bowel malignancy following stricturoplasty and bypassed 
loops[45-51]. As such, biopsies of the stricture should 
occur prior to dilation[22]. There has been no evidence to 
suggest obtaining biopsies prior to EBD increases the risk 
for perforation. 
concLuSIon
EBD remains a safe and effective modality of trea-
ting CD strictures in appropriately selected patients. 
Although it may not be able to prevent operative man-
agement in all patients, it can significantly delay it. For 
an isolated intestinal fibrostenotic CD stricture less than 
or equal to 5 cm in length without adjacent fistulization 
or perforation, EBD should be considered as first-line 
therapy (Table 3). 
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